CBP-201 is a monoclonal antibody against IL-4Rα, a receptor found on immune cells that mediates the biological activities of both IL-4 and IL-13, two important cytokines that drive a broad range of allergic inflammation such as asthma and atopic dermatitis. Preclinical studies showed that CBP-201 is extremely potent in inhibiting IL-4Rα signaling (IC50 is approximately 50 pM).  In the first-in-human study, CBP-201 demonstrated excellent tolerability and PK and PD profiles. Dosisng in patients with moderate to severe atopic dermatitis is in progress to further determine its safety and immune modulation activity.

TEL/FAX: 0512-53577866

E-MAIL: qchang@connectpharm.com

ADD: Science and Technology Park, East R&D Building , 3rd Floor , 6 Beijing West Road, Taichang, Jiangsu, China 215400

Copyright: Suzhou Connect Biopharmaceuticals, Ltd. 苏ICP备17002143号

Technical support: Epower